Summit Therapeutics announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter for its biologics license application for ivonescimab plus platinum-containing chemotherapy in previously treated, locally advanced or metastatic non-small cell lung cancer (NSCLC). The application was based on the Phase 3 HARMONi trial in patients with EGFR-mutated disease. The trial met its progression-free survival endpoint, but the primary overall survival analysis did not reach statistical significance.
Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics, drew on her experience as a cancer survivor when discussing the need for additional treatment options.
“As a cancer survivor, I understand firsthand how important it is for patients to have access to multiple treatment options, particularly when they are facing diseases with significant unmet medical needs.”
Zanganeh also addressed what additional options can mean for patients with limited alternatives.
According to Summit, the FDA determined that the application could not be approved in its current form. The agency concluded that the progression-free survival improvement, in the absence of a statistically significant overall survival benefit, did not establish substantial evidence of effectiveness or support a favorable benefit-risk profile for the proposed indication. Summit said that no FDA-approved regimen had demonstrated a statistically significant overall survival benefit in this treatment setting.
Ivonescimab After Prior EGFR Inhibitor Therapy
HARMONi was a global, randomized, double-blind phase 3 trial in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who had previously received a third-generation EGFR tyrosine kinase inhibitor. Patients received either ivonescimab plus platinum-containing chemotherapy or placebo plus platinum-containing chemotherapy. Both groups received chemotherapy, allowing the trial to evaluate the effect of adding ivonescimab.
The study had two primary endpoints. Progression-free survival (PFS) measured how long patients lived before their disease progressed or they died. Overall survival (OS) measured how long patients lived after randomization. The two analyses addressed whether adding ivonescimab delayed disease progression and whether it prolonged survival.
Progression-Free Survival Endpoint
Progression-free survival. Ivonescimab plus chemotherapy produced a statistically significant improvement in PFS compared with placebo plus chemotherapy. Summit reported that a post hoc analysis incorporating longer follow-up for Western patients showed a similar magnitude of PFS benefit.
Overall survival. The primary OS analysis numerically favored ivonescimab plus chemotherapy, but the difference did not reach statistical significance. In a post hoc analysis incorporating longer follow-up for Western patients, Summit reported an OS hazard ratio of 0.76 in each of three populations it described: the full study population, Asian patients, and Western patients. The 0.76 estimate came from the post hoc analysis, while the FDA’s stated rationale cited the absence of a statistically significant OS improvement.
Treatment Discontinuations and Fatal Adverse Events
Summit reported that the safety profile of ivonescimab plus chemotherapy was consistent with previous studies and that HARMONi identified no new safety signals. Treatment-related adverse events led 16 patients (7.3%) to discontinue ivonescimab and 11 patients (5.0%) to discontinue placebo.
Treatment-related adverse events were fatal in four patients (1.8%) in the ivonescimab plus chemotherapy group and five patients (2.3%) in the placebo plus chemotherapy group. The release provided these discontinuation and fatal event figures without reporting the overall incidence of grade 3 or higher adverse events or listing the most common treatment-emergent adverse events.
How Ivonescimab Targets PD-1 and VEGF
Ivonescimab is a bispecific antibody that blocks programmed cell death protein 1 (PD-1), an immune checkpoint, and vascular endothelial growth factor (VEGF), which promotes blood vessel formation. The antibody has four binding sites and binds PD-1 with higher affinity in the presence of VEGF, according to Summit. Akeso developed ivonescimab, and China granted its initial marketing authorization in May 2024.
Ivonescimab Remains Investigational in the US as First-Line Trials Continue
The Complete Response Letter concerns the proposed use of ivonescimab plus platinum-containing chemotherapy after prior EGFR inhibitor therapy. Summit is evaluating ivonescimab earlier in the treatment course in two phase 3 metastatic NSCLC trials. HARMONi-3 is testing ivonescimab plus chemotherapy in the first-line setting, with separate analyses for patients with squamous and non-squamous tumors. HARMONi-7 is evaluating first-line ivonescimab monotherapy in patients whose tumors have high PD-L1 expression.
Summit is also studying ivonescimab combinations in other tumor types. The phase 3 HARMONi-GI3 trial is evaluating ivonescimab plus chemotherapy as first-line treatment for unresectable metastatic colorectal cancer. The phase 2/3 HARMONi-GU1 trial is evaluating ivonescimab plus enfortumab vedotin in previously untreated metastatic urothelial carcinoma, and the phase 2 SMT112-216 trial is studying several ivonescimab-based combinations as first-line treatment for metastatic clear cell renal cell carcinoma.
You can also read: Perioperative Ivonescimab Shows Promising Pathological Responses in Resectable NSCLC: Phase II Trial Reports 70.1% MPR and 50.7% pCR.
